Effect of Bevacizumab and Ranibizumab on the Expression of eNOS in Trabecular Meshwork Cells.
10.3341/jkos.2014.55.8.1208
- Author:
Se Eun KIM
1
;
Jae Woo KIM
Author Information
1. Department of Ophthalmology, Catholic University of Daegu School of Medicine, Daegu, Korea. jwkim@cu.ac.kr
- Publication Type:Original Article
- Keywords:
Bevacizumab;
eNOS;
Nitric oxide;
Ranibizumab;
Trabecular meshwork
- MeSH:
Humans;
Nitric Oxide;
RNA, Messenger;
Trabecular Meshwork*;
Vascular Endothelial Growth Factor A;
Bevacizumab;
Ranibizumab
- From:Journal of the Korean Ophthalmological Society
2014;55(8):1208-1212
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To compare the effects of bevacizumab and ranibizumab on the expression of eNOS in cultured human trabecular meshwork cells (HTMC). METHODS: Primarily cultured HTMC were exposed to 0.5 mg/mL bevacizumab and ranibizumab using 1% serum-containing media for 30 minutes. Expression of eNOS mRNA was assessed with RT-PCR. Additionally, after exposure to 20 ng/mL of vascular endothelial growth factor (VEGF) and 0.5 mg/mL bevacizumab and ranibizumab, the production of nitric oxide was assessed with Griess assay. RESULTS: VEGF increased the production of nitric oxide in HTMC. Bevacizumab and ranibizumab decreased the expression of eNOS mRNA and production of nitric oxide (p < 0.05) in HTMC. The decrease in eNOS mRNA expression and production of nitric oxide was not significant between bevacizumab and ranibizumab (p > 0.05). CONCLUSIONS: In HTMC, both bevacizumab and ranibizumab decreased the expression of eNOS mRNA with no significant difference observed between the two drugs.
